Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction
Netherlands Heart Journal , Volume 22 - Issue 4 p. 167- 173
Aims Everolimus-eluting stents (EES) were superior to sirolimus-eluting stents (SES) in a dedicated myocardial infarction trial, a finding that was not observed in trials with low percentages of ST-elevation myocardial infarction (STEMI). Therefore, this study sought to investigate the influence of clinical presentation on outcome after EES and SES implantation. Methods A pooled population of 1602 randomised patients was formed from XAMI (acute MI trial) and APPENDIXAMI (all-comer trial). Primary outcome was cardiac mortality, MI and target vessel revascularisation at 2 years. Secondary endpoints included definite/probable stent thrombosis (ST). Adjustment was done using Cox regression. Results In total, 902 EES and 700 SES patientswere included, of which 44%STEMI patients (EES 455; SES 257) and 56% without STEMI (EES 447; SES 443). In the pooled population, EES and SES showed similar outcomes during followup. Moreover, no differences in the endpoints were observed after stratification according to presentation. Although a trend toward reduced early definite/probable ST was observed in EES compared with SES in STEMI patients, long-term ST rates were low and comparable. Conclusions EES and SES showed a similar outcome during 2-year follow-up, regardless of clinical presentation. Longterm safety was excellent for both devices, despite wide inclusion criteria and a large sub-population of STEMI patients.
|Coronary artery disease, Drug-eluting stents, Percutaneous coronary intervention|
|Netherlands Heart Journal|
|Organisation||Department of Cardiology|
Velders, F.P, van Boven, A.J, Brouwer, J, Smits, P.C, van't Hof, A.W.J, de Vries, C.J, … Hofma, S.H. (2014). Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction. Netherlands Heart Journal, 22(4), 167–173. doi:10.1007/s12471-014-0525-0